PET Imaging of Cannabinoid CB1 Receptors Using [11C]MePPEP
| Status: | Completed |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 4/6/2019 |
| Start Date: | January 8, 2008 |
| End Date: | January 22, 2013 |
PET Test/Retest Brain Imaging of Cannabinoid CB1 Receptors Using [11C]MePPEP
The purpose of this protocol is to measure brain CB1 receptors in the hope to better
understand how they work, so that one day we can understand how the CB1 receptors are
involved in psychiatric, neurological, and behavioral disorders.
understand how they work, so that one day we can understand how the CB1 receptors are
involved in psychiatric, neurological, and behavioral disorders.
MePPEP is a ligand that is highly selective for the cannabinoid type 1 (CB1) receptor. This
receptor is considered the most common G-coupled protein receptor in the brain (Pacher et
al., 2006). The CB1 receptor is the site of action of Delta-9-tetrahydrocannbinol (THC), the
active compound in marijuana, and is found primarily on the presynaptic terminals of
dopaminergic, glutamatergic, GABAergic neurons (Howlett et al., 2002). The function of the
CB1 receptor is not entirely clear; however, it has been implicated in several neurological
and psychiatric disorders, and a selective inverse agonist, rimonabant, is currently in use
in Europe for the treatment of obesity (Van Gaal et al., 2005). [11C]MePPEP was developed to
enhance our understanding of the in vivo characteristics of the CB1 receptor (e.g., receptor
density and receptor occupancy with pharmaceuticals).
The purpose of this protocol is to establish an accurate method to measure CB1 receptor
levels in brain by performing test/retest brain imaging studies. The results of this overall
study are required to apply this PET ligand in various neurological and psychiatric disorders
in the future.
receptor is considered the most common G-coupled protein receptor in the brain (Pacher et
al., 2006). The CB1 receptor is the site of action of Delta-9-tetrahydrocannbinol (THC), the
active compound in marijuana, and is found primarily on the presynaptic terminals of
dopaminergic, glutamatergic, GABAergic neurons (Howlett et al., 2002). The function of the
CB1 receptor is not entirely clear; however, it has been implicated in several neurological
and psychiatric disorders, and a selective inverse agonist, rimonabant, is currently in use
in Europe for the treatment of obesity (Van Gaal et al., 2005). [11C]MePPEP was developed to
enhance our understanding of the in vivo characteristics of the CB1 receptor (e.g., receptor
density and receptor occupancy with pharmaceuticals).
The purpose of this protocol is to establish an accurate method to measure CB1 receptor
levels in brain by performing test/retest brain imaging studies. The results of this overall
study are required to apply this PET ligand in various neurological and psychiatric disorders
in the future.
- INCLUSION CRITERIA:
All subjects must be healthy and aged 18 65 years, with history/physical exam, ECG, and
laboratory tests within one year of the PET scan. The volunteer must sign an informed
consent form.
EXCLUSION CRITERIA:
- Current psychiatric illness, substance abuse including marijuana use, or severe
systemic disease based on history and physical exam.
- Laboratory tests with clinically significant abnormalities or positive urine
toxicology screen.
- Prior participation in other research protocols in the last year such that radiation
exposure would exceed the annual limits.
- Pregnancy and breast feeding.
- Claustrophobia.
- Presence of ferromagnetic metal in the body or heart pacemaker.
- Positive HIV test.
- Employee of the investigative site or an immediate family member of an employee of the
investigative site. Immediate family member is defined as a spouse, parent, child, or
sibling, whether biological or legally adopted.
- Employee of Eli Lilly and Company.
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
Click here to add this to my saved trials
